Panacea Acquisition Corp (NUVB) News

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Nuvation Bio Reports First Quarter 2024 Financial Results and Provides Business Update

Acquisition of AnHeart Therapeutics transformed Nuvation Bio into a late-stage, global oncology company with potential to become a commercial...

Nuvation Bio to Present Updated Data on Taletrectinib, a ROS1 inhibitor, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Nuvation Bio Inc. (NYSE: NUVB), a late-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology by...

Nuvation Bio Completes Acquisition of AnHeart Therapeutics

Transforms Nuvation Bio into late-stage global oncology company with potential to become a commercial organization by the end of 2025...

Nuvation Bio Announces Appointment of Colleen Sjogren as Chief Commercial Officer

Ms. Sjogren brings nearly 30 years of biopharmaceutical experience building commercial organizations and leading successful oncology launches...

Nuvation Bio to Acquire AnHeart Therapeutics in All-Stock Transaction

Acquisition transforms Nuvation Bio into late-stage global oncology company with potential to become a commercial organization by the end of 2025...

Nuvation Bio Doses First Patient in Phase 1/2 Study of NUV-1511 for the Treatment of Advanced Solid Tumors

NUV-1511 is the Company’s first drug-drug conjugate (DDC) to enter the clinic Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company...

Form S-8 - Securities to be offered to employees in employee benefit plans

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Form 8-K - Current report